1. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023
- Author
-
Smith, Todd G., Gigante, Crystal M., Wynn, Nhien T., Matheny, Audrey, Davidson, Whitni, Yang, Yong, Condori, Rene Edgar, O'Connell, Kyle, Kovar, Lynsey, Williams, Tracie L., Yu, Yon C., Petersen, Brett W., Baird, Nicolle, Lowe, David, Li, Yu, Satheshkumar, Panayampalli S., and Hutson, Christina L.
- Subjects
SIGA Technologies Inc. ,United States. Centers for Disease Control and Prevention ,Health aspects ,Tecovirimat -- Health aspects ,Amino acids -- Health aspects ,Infection -- Health aspects ,Pharmaceutical industry -- Health aspects - Abstract
In May 2022, an outbreak of mpox disease, caused by infection with monkeypox virus (MPXV) clade IIb (formerly West Africa clade), was identified in the United States (1). Since that [...]
- Published
- 2023
- Full Text
- View/download PDF